Clinical Trial: A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis

U.S., Sept. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07158242) titled 'A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis' on Aug. 28.

Brief Summary: This Phase III, randomized, double-blind, multicenter, induction and maintenance study will evaluate the safety and efficacy of Afimkibart (RO7790121) in pediatric participants with moderate to severe active ulcerative colitis (UC).

Study Start Date: March 31, 2026

Study Type: INTERVENTIONAL

Condition: Moderately to Severely Active Ulcerative Colitis

Intervention: DRUG: Afimkibart

Afimkibart will be administered as IV infusion. Afimkibart will be ...